Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 9 people enrolled
- Started
- 9 Aug 2023
- Ended
- 4 Mar 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Integrative Therapy
- Record updated
- 7 April 2025
- Why it stopped
- The PIs left the institution.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Admitted to local area Bone Marrow Transplant Unit or Hematology/Oncology during the study period
- Diagnosed with acute leukemia
- Receiving high-grade MDS induction chemotherapy
- Within first 3 days of chemotherapy initiation
- Age > 18 years
- Able to speak/read English
Who cannot take part
- -Altered mental status or diminished level of consciousness as established by daily progress note documented by health care provider, nursing assessment, or at the discretion of the Integrative Therapies practitioner
Where in United States
- University of FloridaGainesville, United States
About the trial
What the trial wants to find out
This pilot study will use a mixed methods approach to evaluate the feasibility and acceptability of Integrative Therapies, a bedside service offering mindfulness-based interventions (still meditation, meditative movement, relaxation techniques, and massage therapy) as non-pharmacologic treatment for symptom management in newly diagnosed adult Acute Myeloid Leukemia (AML) patients undergoing induction chemotherapy
The 2 groups in the trial
- Standard of care with integrative therapyTreatment being tested
For the intervention group, an initial interview will be conducted and the Patient-Reported Outcomes Measurement Information System (PROMIS) and Memorial Symptom Assessment Scale (MSAS) questionnaires will be administered at enrollment. Integrative Therapies will then begin offering two to four sessions weekly. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again along with an acceptability questionnaire. At 21 (+-2) days after the start of induction chemotherapy, a second interview will be conducted.
Treatment: Integrative Therapy
- Standard of care onlyNo study treatment, for comparison
For the standard care group, an initial interview will be conducted and the PROMIS and MSAS questionnaires will be administered at enrollment. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again. At 21 days (+-2 days) after the start of induction chemotherapy, a second interview will be conducted.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia Undergoing High-grade MDS Induction Chemotherapy
- Record updated
- 7 April 2025